内脂素与非酒精性脂肪性肝病患者甲状腺功能异常的关系

任仕萍; 马臻棋; 王学红

doi:10.3969/j.issn.1001-5256.2020.06.042

内脂素与非酒精性脂肪性肝病患者甲状腺功能异常的关系

DOI: 10.3969/j.issn.1001-5256.2020.06.042

1. 青海大学研究生院
2. 青海大学附属医院消化内科

基金项目:

青海省消化系统疾病临床医学研究中心(2019-SF-L3)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 557
- HTML全文浏览量: 15
- PDF下载量: 118
- 被引次数: 0
出版历程
- 收稿日期: 2019-12-20
- 出版日期: 2020-06-20

Association of visfatin with thyroid dysfunction in patients with nonalcoholic fatty liver disease

Graduate School of Qinghai University
Department of Gastroenterology,Qinghai University Affiliated Hospital

Research funding:

摘要

摘要:
目前研究发现,内脂素参与了非酒精性脂肪性肝病(NAFLD)的脂质代谢过程,约25%的NAFLD患者伴甲状腺功能异常。内脂素还被发现通过自分泌或者旁分泌途径参与自身免疫调节,这与甲状腺作为人体的内分泌腺,参与调节全身各系统存在一定关联。通过文献回顾初步探究内脂素与NAFLD患者甲状腺功能异常的关系,提示内脂素的检测有助于早期发现NAFLD患者甲状腺功能异常。
- 非酒精性脂肪性肝病 /
- 烟酰胺磷酸核糖基转移酶 /
- 甲状腺激素类
Abstract:
Recent studies have found that visfatin is involved in lipid metabolism in patients with nonalcoholic fatty liver disease( NAFLD),and about 25% of NAFLD patients have thyroid dysfunction. It has also been found that visfatin is involved in autoimmune regulation through the autocrine or paracrine pathways,which is associated with the involvement of the thyroid gland in autoimmune regulation of the body. This article preliminarily explores the association of visfatin with thyroid dysfunction in NAFLD patients and points out that the measurement of visfatin may help with the early identification of thyroid dysfunction in NAFLD patients.
- non-alcoholic fatty liver disease /
- nicotinamide phosphoribosyltransferase /
- thyroid hormones

HTML全文

参考文献(40)

[1] YOUNOSSI ZM,STEPANOVA M,AFENDY M,et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008[J]. Clin Gastroenterol Hepatol,2011,9(6):524-530. e1; quiz e60.

[2] BOUTARI C,PERAKAKIS N,MANTZOROS CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease[J]. Endocrinol Metab(Seoul),2018,33(1):33-43.

[3] THONDAM SK,CUTHBERTSON DJ,WILDING J. The influence of Glucose-dependent Insulinotropic Polypeptide(GIP)on human adipose tissue and fat metabolism:Implications for obesity,type 2 diabetes and non-alcoholic fatty liver disease(NAFLD)[J]. Peptides,2019.[Online ahead of print]

[4] FUKUHARA A,MATSUDA M,NISHIZAWA M,et al. Visfatin:A protein secreted by visceral fat that mimics the effects of insulin[J]. Science,2005,307(5708):426-430.

[5] PRAVENEC M,KAZDOVL,LANDA V,et al. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat[J]. J Biol Chem,2003,278(46):45209-45215.

[6] MOSCHEN AR,GERNER RR,TILG H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders[J]. Curr Pharm Des,2010,16(17):1913-1920.

[7] NEUSCHWANDER-TETRI BA,CLARK JM,BASS NM,et al.Clinical,laboratory and histological associations in adults with nonalcoholic fatty liver disease[J]. Hepatology,2010,52(3):913-924.

[8] LIU K,LI HF,ZHANG H. Analysis of the relationship between serum visfatin,GADA and carotid intima-media thickness in patients with chronic hepatitis C[J]. J Clin Exp Med,2019,18(13):1390-1394.(in Chinese)刘岢，李会芳，张辉．慢性丙型肝炎患者血清内脂素和谷氨酸脱羧酶抗体与颈动脉内膜中层厚度的关系分析[J]．临床和实验医学杂志，2019,18(13):1390-1394.

[9] HEO YJ,CHOI SE,JEON JY,et al. Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes[J]. J Diabetes Res,2019,2019:4021623.

[10] IINO C,ENDO T,MIKAMI K,et al. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease:A large BMI-and sex-matched population study[J]. Hepatol Int,2019,13(6):748-756.

[11] TONG J,GUO JJ. Key molecular pathways in the progression of non-alcoholic steatohepatitis[J]. Eur Rev Med Pharmacol Sci,2019,23(19):8515-8522.

[12] HETTA HF,EZ-ELDEEN ME,MOHAMED GA,et al. Visfatin serum levels in obese type 2 diabetic patients:Relation to proinflammatory cytokines and insulin resistance[J]. Egypt J Immunol,2018,25(2):141-151.

[13] XIAO J,SUN B,LI M,et al. A novel adipocytokine visfatin protects against H(2)O(2)-induced myocardial apoptosis:A missing link between obesity and cardiovascular disease[J]. J Cell Physiol,2013,228(3):495-501.

[14] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J]. J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会．非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]．临床肝胆病杂志，2018,34(10):2103-2108.

[15] GARTEN A,SCHUSTER S,PENKE M,et al. Physiological and pathophysiological roles of NAMPT and NAD metabolism[J]. Nat Rev Endocrinol,2015,11(9):535-546.

[16] BOUTARI C,PERAKAKIS N,MANTZOROS CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease[J]. Endocrinol Metab(Seoul),2018,33(1):33-43.

[17] AKBAL E,KOAK E,TA爦A,et al. Visfatin levels in nonalcoholic fatty liver disease[J]. J Clin Lab Anal,2012,26(2):115-119.

[18] MARCUS C,EHRN H,BOLME P,et al. Regulation of lipolysis during the neonatal period. Importance of thyrotropin[J].J Clin Invest,1988,82(5):1793-1797.

[19] CENGIZ M,OZENIRLER S,KOCABIYIK M. Serumβ-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis[J]. Eur J Gastroenterol Hepatol,2016,28(1):57-63.

[20] QIU Y,WANG SF,YU C,et al. Association of circulating adipsin,visfatin,and adiponectin with nonalcoholic fatty liver disease in adults:A case-control study[J]. Ann Nutr Metab,2019,74(1):44-52.

[21] KUKLA M,CIUPIN'SKA-KAJOR M,KAJOR M,et al. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery[J]. Pol J Pathol,2010,61(3):147-153.

[22] ROTTER SV,GOGG S,JANSSON PA,et al. Visfatin is an adipokine,but it is not regulated by thiazolidinedione[J]. J Clin Endocrinol Metab,2006,91(3):1181-1184.

[23] GENC H,DOGRU T,KARA M,et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease[J]. Ann Hepatol,2013,12(4):548-555.

[24] PENG L,XU TT,ZHAO WK,et al. Advances in the research of prolactin and the pathogenesis of essential hypertension[J]. J Clin Cardiol,2019,35(1):8-11.(in Chinese)彭丽，徐彤彤，赵位昆，等．内脂素与原发性高血压发病机制的研究进展[J]．临床心血管病杂志，2019,35(1):8-11.

[25] MOUSAVI Z,GANJI A,FARROKH TEHRANI D,et al. Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome[J]. Med J Islam Repub Iran,2017,31:28.

[26] BOUTARI C,TZIOMALOS K,ATHYROS VG. The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease[J]. Hippokratia,2016,20(4):259-263.

[27] SINHA RA,BRUINSTROOP E,SINGH BK,et al. Nonalcoholic fatty liver disease and hypercholesterolemia:Roles of thyroid hormones,metabolites,and agonists[J]. Thyroid,2019,29(9):1173-1191.

[28] AL DOGHAITHER HA,ALSHAIKH EM,OMAR UM,et al. Insulin resistance and its correlation with chemerin and visfatin in Saudi patients with hyperthyroidism[J]. Int J Health Sci(Qassim),2019,13(5):18-21.

[29] SIDDIQUI K,GEORGE TP,JOY SS,et al. Variation in the level of thyroid markers in association with inflammation in patients with type 2 diabetes[J]. Endocr Metab Immune Disord Drug Targets,2019.[Online ahead of print]

[30] YOUNOSSI ZM,JARRAR M,NUGENT C,et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis(NASH)[J]. Obes Surg,2008,18(11):1430-1437.

[31] KNUDSEN N,LAURBERG P,RASMUSSEN LB,et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population[J]. J Clin Endocrinol Metab,2005,90(7):4019-4024.

[32] SAWICKA-GUTAJ N,ZYBEK-KOCIK A,KLIMOWICZ A,et al. Circulating visfatin in hypothyroidism is associated with free thyroid hormones and antithyroperoxidase antibodies[J]. Int J Endocrinol,2016,2016:7402469.

[33] NOWELL M,EVANS L,WILLIAMS A. PBEF/NAMPT/visfatin:A promising drug target for treating rheumatoid arthritis?[J].Future Med Chem,2012,4(6):751-769.

[34] HSIEH SD,YOSHINAGA H. Abdominal fat distribution and coronary heart disease risk factors in men-waist/height ratio as a simple and useful predictor[J]. Int J Obes Relat Metab Disord,1995,19(8):585-589.

[35] JIN H,JIANG B,TANG J,et al. Serum visfatin concentrations in obese adolescents and its correlation with age and highdensity lipoprotein cholesterol[J]. Diabetes Res Clin Pract,2008,79(3):412-418.

[36] CHU CH,LEE JK,WANG MC,et al. Change of visfatin,Creactive protein concentrations,and insulin sensitivity in patients with hyperthyroidism[J]. Metabolism,2008,57(10):1380-1383.

[37] CINAR N,GURLEK A. Association between novel adipocytokines adiponectin,vaspin,visfatin,and thyroid:An experimental and clinical update[J]. Endocr Connect,2013,2(4):r30-r38.

[38] CAIXS A,TIRADO R,VENDRELL J,et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not related to insulin resistance,anthropometric or inflammatory parameters[J]. Clin Endocrinol(Oxf),2009,71(5):733-738.

[39] SAWICKA-GUTAJ N,ZYBEK-KOCIK A,KLIMOWICZ A,et al. Circulating visfatin in hypothyroidism is associated with free thyroid hormones and antithyroperoxidase antibodies[J]. Int J Endocrinol,2016,2016:7402469.

[40] KOZAKO T,AIKAWA A,OHSUGI T,et al. High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor[J]. Eur J Pharmacol,2019,865:172738.

施引文献

资源附件(0)

访问统计